SG11201605588YA - Compositions and methods for treatment of abnormal cell growth - Google Patents

Compositions and methods for treatment of abnormal cell growth

Info

Publication number
SG11201605588YA
SG11201605588YA SG11201605588YA SG11201605588YA SG11201605588YA SG 11201605588Y A SG11201605588Y A SG 11201605588YA SG 11201605588Y A SG11201605588Y A SG 11201605588YA SG 11201605588Y A SG11201605588Y A SG 11201605588YA SG 11201605588Y A SG11201605588Y A SG 11201605588YA
Authority
SG
Singapore
Prior art keywords
compositions
treatment
methods
cell growth
abnormal cell
Prior art date
Application number
SG11201605588YA
Other languages
English (en)
Inventor
Mahesh Padval
Paul Okwabi Nkansah
Original Assignee
Verastem Inc
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc, Pfizer filed Critical Verastem Inc
Publication of SG11201605588YA publication Critical patent/SG11201605588YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
SG11201605588YA 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth SG11201605588YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925467P 2014-01-09 2014-01-09
PCT/US2015/010810 WO2015106096A1 (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
SG11201605588YA true SG11201605588YA (en) 2016-08-30

Family

ID=52434976

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201605588YA SG11201605588YA (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth
SG10201805890QA SG10201805890QA (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201805890QA SG10201805890QA (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Country Status (15)

Country Link
US (3) US20150190346A1 (enrdf_load_stackoverflow)
EP (2) EP3900726A1 (enrdf_load_stackoverflow)
JP (5) JP6647204B2 (enrdf_load_stackoverflow)
KR (3) KR20240159639A (enrdf_load_stackoverflow)
CN (3) CN115708827A (enrdf_load_stackoverflow)
AU (4) AU2015204597B2 (enrdf_load_stackoverflow)
BR (1) BR112016016021B1 (enrdf_load_stackoverflow)
CA (1) CA2936283C (enrdf_load_stackoverflow)
DK (1) DK3091981T3 (enrdf_load_stackoverflow)
ES (1) ES2870562T3 (enrdf_load_stackoverflow)
IL (2) IL246667B (enrdf_load_stackoverflow)
MX (2) MX384259B (enrdf_load_stackoverflow)
NZ (2) NZ760233A (enrdf_load_stackoverflow)
SG (2) SG11201605588YA (enrdf_load_stackoverflow)
WO (1) WO2015106096A1 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7550393B2 (ja) * 2018-05-15 2024-09-13 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド 低分子ｅｇｆｒ阻害剤を含む医薬組成物及びその製造方法
JP2022547358A (ja) * 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
WO2021191812A1 (en) * 2020-03-27 2021-09-30 Pfizer Inc. Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
EP1653926A1 (en) * 2003-08-04 2006-05-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
EA016679B1 (ru) * 2007-04-18 2012-06-29 Пфайзер Продактс Инк. Сульфониламидные производные для лечения аномального роста клеток
MX366161B (es) * 2008-08-13 2019-07-01 Vertex Pharmaceutical Incorporated Composicion farmaceutica y su administracion.
WO2011112922A2 (en) * 2010-03-11 2011-09-15 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
JP2013536231A (ja) * 2010-08-23 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与
AU2012225459A1 (en) * 2011-03-08 2013-10-10 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions

Also Published As

Publication number Publication date
AU2022256144A1 (en) 2022-11-24
BR112016016021A8 (pt) 2018-04-17
CA2936283A1 (en) 2015-07-16
JP6647204B2 (ja) 2020-02-14
NZ760233A (en) 2022-04-29
BR112016016021B1 (pt) 2023-01-10
KR102444494B1 (ko) 2022-09-20
NZ721934A (en) 2022-04-29
EP3900726A1 (en) 2021-10-27
EP3091981B1 (en) 2021-03-10
SG10201805890QA (en) 2018-08-30
CA2936283C (en) 2023-02-28
US20200038331A1 (en) 2020-02-06
US20150190346A1 (en) 2015-07-09
AU2020210153A1 (en) 2020-08-13
AU2015204597A1 (en) 2016-07-21
BR112016016021A2 (pt) 2017-09-19
JP2025084892A (ja) 2025-06-03
WO2015106096A1 (en) 2015-07-16
CN106102744A (zh) 2016-11-09
JP2020007355A (ja) 2020-01-16
MX384259B (es) 2025-03-14
MX2021008225A (es) 2021-08-11
EP3091981A1 (en) 2016-11-16
JP2017502062A (ja) 2017-01-19
AU2020210153B2 (en) 2022-07-21
KR20220130251A (ko) 2022-09-26
CN115708827A (zh) 2023-02-24
ES2870562T3 (es) 2021-10-27
IL246667A0 (en) 2016-08-31
AU2025204843A1 (en) 2025-07-17
MX2016009056A (es) 2017-01-23
CN119868364A (zh) 2025-04-25
KR20240159639A (ko) 2024-11-05
IL246667B (en) 2022-05-01
US20230104303A1 (en) 2023-04-06
KR20160104725A (ko) 2016-09-05
IL292054A (en) 2022-06-01
JP2023065568A (ja) 2023-05-12
DK3091981T3 (da) 2021-05-31
JP2022001587A (ja) 2022-01-06
AU2022256144B2 (en) 2025-04-03
AU2015204597B2 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
IL251951A0 (en) Methods and compositions for natural killer cells
GB201609438D0 (en) Compositions and methods for cell targeted HPV treatment
IL246352B (en) Preparations and methods for preparing airway cells
EP3331582A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRANSPLANTATION CELLS
HUE051232T2 (hu) Béta-talasszémia kezelésére szolgáló eljárások és készítmények
EP3102232A4 (en) Methods and compositions for treating abnormal cell growth
AP2017009674A0 (en) Methods and compositions for treating ulcers
ZA201700183B (en) Acetylcholinesterase inhibitors for treatment of dermatological conditions
IL252011A0 (en) Methods and compositions especially for the treatment of attention deficit disorder
SI3586821T1 (sl) Sestavki in postopki za stimuliranje matičnih celic
EP3201225A4 (en) Methods and compositions for treatment of conditions associated with elevated triglycerides
EP3226972A4 (en) Methods and compositions for treating migraine and conditions associated with pain
IL292054A (en) Compositions for treatment of abnormal cell growth
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
EP3142674A4 (en) Methods and compositions for treatment of macrophage-related disorders
IL252707B (en) Compositions and methods for treating diseases
IL248846A0 (en) Methods and preparations of dezotraline for the treatment of adhd
HK40036798B (en) Methods for treating abnormal cell growth
HK1234730A1 (en) Methods and compositions of dasotraline for treatment of adhd
GB201418268D0 (en) Composition & methods of treatment
GB201418272D0 (en) Composition & methods of treatment